

CURRICULUM VITAE

Bingcheng Wang, Ph.D.

PRESENT TITLE AND PRIMARY AFFILIATIONS:

Professor (Tenured)
and John A. and Josephine B. Wootton Endowed Chair of Research
Departments of Medicine, Pharmacology and Oncology
Case Western Reserve University School of Medicine

Leader
Genitourinary Malignancies Program
National Cancer Institute (NCI)-Designated Case Comprehensive Cancer
Center
Case Western Reserve University School of Medicine

OFFICE ADDRESS:

Rammelkamp Center for Research, R421
MetroHealth Medical Center
Case Western Reserve University School of Medicine
2500 MetroHealth Drive
Cleveland, OH 44109
Phone 216-778-4256 (off)
 216-778-8867 (lab)
 216-952-9820 (mobile)
FAX 216-778-4321
E-mail bxw14@case.edu

HOME ADDRESS:

38550 Flanders Drive
Solon, OH 44139

CITIZENSHIP:

United States

EDUCATION:

Ph.D. 1991 University of Wisconsin-Madison, Toxicology/Oncology.
B.S. 1982 Nanjing University, Chemistry, *summa cum laude*

PROFESSIONAL APPOINTMENT:

1986 Graduate Research Assistant, University of Wisconsin-Madison
1991 Postdoctoral Fellow, The Burnham Institute (formerly La Jolla
 Cancer Research Foundation)
1994 Research Associate, The Burnham Institute

1997	Assistant Professor, Department of Medicine, MetroHealth Medical Center, Case Western Reserve University School of Medicine
2000	Assistant Professor, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine.
2000	Assistant Professor, Department of Pharmacology, Case Western Reserve University School of Medicine.
2003	Associate Professor with Tenure, Department of Medicine, Department of Pharmacology, and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine.
2005	Adjunct Associate Professor, Department of Chemistry, Graduate School Faculty, Cleveland State University.
2009	Professor with Tenure, Department of Medicine and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine.
2010	Adjunct Professor and Trainer, Molecular Medicine Graduate Program, The Lerner Research Institute, Cleveland Clinic Foundation
2010-present	Professor, Department of Pharmacology, Case Western Reserve University School of Medicine.
2011-present	Program Leader, Genitourinary Malignancies Program, National Cancer Institute (NCI)-Designated Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine
2012-present	John A. and Josephine Wootton Endowed Chair of Research, Case Western Reserve University School of Medicine.

HONORS AND AWARDS:

1979-1981	President's Highest Honor Awards (Nanjing University)
1984	Educational Ministry Oversea Pre-doctoral Scholarship.
1987	Toxicology/Oncology Training Program Fellowship, University of Wisconsin-Madison
1998	American Cancer Society Award
1998	Kidney Foundation New Investigator Award
2001	CaP CURE Award
2004	Prostate Cancer Foundation Award
2007	Joan's Legacy Foundation Award
2008	FAMRI foundation Award
2010	Prayers From Maria Foundation Award
2012	John A and Josephine B. Wootton Endowed Chair of Research, Case Western Reserve University.

PATENTS:

U.S. Patent Number 5,215,904. "*in situ* gene transfer to breast epithelial cells, which was one of the first three biotech patents issued in the U.S." Inventors: Michael N. Gould and Bing-Cheng Wang.

US Patent Number 8,222,253 B2. “Targeting EphA kinase by dobutamine and other small compounds”, Issued July 17, 2012. Inventors: Myshkin, Eugene; Miao, Hui; Wang, Bing-Cheng

US Patent Number 12/519,294. “Peptide and Small Molecule Agonists of EphA and Their Uses in Disease”. Inventors: Myshkin, Eugene; Wang, Bing-Cheng

US Patent Number 12/795,142. “EphA Kinase Cancer Diagnostic”. Inventors: Miao, Hui; Wang, Bing-Cheng

EXTRAMURAL GRANT SUPPORT:

CURRENT SUPPORT:

NIH/NCI 1R01CA155676-01 (Wang) “EphA2 kinase in prostate cancer” Role in Project: PI	9/1/11 – 6/30/16 \$207,500/yr (direct)
NIH-NCI R01 CA152371 (Wang) “Akt-EphA2 Crosstalk in Glioma Invasion” Role in Project: PI	6/1/10 to 4/30/15 \$207,500/yr (direct)
NIH-NIDDK R01 DK077876 (Wang) “Eph Kinases in Renal Epithelial Cells” Role in Project: PI	6/01/08 to 5/31/13 \$212,000/yr (direct)
Prayers from Maria Foundation Award (Wang) “EphA2 in Childhood Glioma” Role in Project: PI	4/1/10 to 3/30/13 \$50,000/yr (direct)
FAMRI Foundation Research Award (Wang) “Targeting EphA2 for Lung Cancer Therapy” Role in Project: PI	7/01/08 to 6/30/13 \$100,000/yr (direct)
NIH-NIDDK R01DK095832 (Bruggeman) “Cell Junction Proteins in Podocyte Injury Repair” The goal of this project is to characterize how cell junction proteins contribute to kidney diseases. Role: Co-investigator	7/1/12 to 6/30/16 \$13,737/yr (direct)
NIH-NCI 5P30CA043703-22 (Gerson) Case Comprehensive Cancer Center Support Grant Role: Co-Leader of Genitourinary Malignancies Program	7/1/11 to 3/31/2018 \$13,737/yr (direct)
NIH-NCI 1R01CA175120 (Gladson)	3/1/13 to 2/28/18

“Mechanism promoting angiogenesis in glioblastoma”

The goal of this project is to test the hypothesis that angiogenesis in GBM is promoted by increased endothelial cell motility that is driven by GSC-secreted factors that upregulate pro- angiogenic molecules such as L1CAM and ephrin-B2 on endothelial cells.

Role: co- Principle Investigator

PAST SUPPORT:

NIH-NCI R01 CA92259 04/01/02 to 3/31/09

“EphA2 agonists as novel inhibitors of tumor progression”

Role in Project: PI

NIH-NCI R01 CA96533 10/01/01 to 9/30/07

“Eph kinase signaling in prostate cancer”

Role in Project: PI

Joan’s Legacy Foundation 12/01/07 to 11/30/09

“EphA2 Regulation of Lung Cancer Development and progression”

Role in Project: PI

USAMRMC, Department of Defense Prostate Cancer Research Program,
DAMD17-99-1-9019

New Investigator Award, Competitive Phase II 9/1/01 to 8/31/05

“Assessing the Role of EphA2 Receptor Tyrosine Kinase in Prostate Cancer
Initiation and Progression Using Genetically Engineered Mice”

Role in Project: PI

NIH-NIDDK P50 DK54178 9/1/98 to 8/31/04

“CWRU O’Brian Renal Research Center”

Role in Project: PI of Peptide Biochemistry Core. Project PI, Sedor

Prostate Cancer Foundation, Research Award, 2004

“EphA1 Kinase in Prostate Cancer”

Role in Project: PI

NIH-NIDDK R21 DK57933 9/30/99 to 8/31/02

“Novel Therapy for Immune Complex-Induced Kidney Diseases”

Role in Project: PI

NIH-NIAMS R01 AR46803 9/30/99 to 8/31/01

“Support of osteoclast differentiation by mesenchymal cells”

Role in Project: Co-Investigator, PI: Greenfield.

CaP CURE New Investigator Award 2001

“IgG fusion peptide agonists of EphA2 receptor tyrosine kinase as novel therapeutics”

Role in Project: PI

March of Dimes Research Grant 6-FY01-274 06/01/01 to 05/31/02

“Regulation of osteoclast differentiation in osteopetrosis”

Role in Project: Co-Investigator, PI: Green

American Heart Association Grant in Aid, 9806275 6/01/01 to 05/31/02

“Regulation of α_v integrin-mediated cell adhesion and migration by Eph kinases”.

Role in Project: PI

NIH-NIDDK R01 DK54213 10/01/98 to 09/30/02

“The extracellular matrix in inflammatory bowel disease”

Role in Project: Co-Investigator, PI: Levine

USAMRMC, Department of Defense Prostate Cancer Research Program,
DAMD17-99-1-9019

New Investigator Award, Phase I

2/1-99 to 8/31-01

“Eph Kinases as Inhibitors of Cell Migration and Targets to Prevent Prostate Cancer Metastasis”

Role in Project: PI

TEACHING EXPERIENCE

Lectures

Toxicology 631, Environmental Toxicology Center, Univ. Wisconsin-Madison, Teaching Assistant, 1988-1990. Class: 20-30 graduate students.

Cell and Molecular Biology (C BIO 453/454). Lecturer. Basic Science Training Program (BSTP), Case Western Reserve University School of Medicine, 2000-2013. Six hours of lecture and two hours of discussion each year.

Class: All freshman graduate students of the Medical School, class size 40-70 PhD, MD/PhD, and MS students.

Cancer Biology and Therapeutics (PHRM 520). Lecturer. Department of Pharmacology and Ireland Cancer Center, Case Western Reserve University School of Medicine, 2001, 2003, 2005, 2007, 2009, 2011, 2013, Four hours of lecture, 2 hours of discussion.

Class: 15-20 senior Ph.D. students.

Cell Surfaces and Matrices (M BIO 518). Lecturer. Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine. 2000, 2002, 2004, 2006. Two hours of lecture.

Class: 6-15 senior Ph.D. students.

Renal Hormone I. Lecturer. Medical School Students, Case School of Medicine. Two hours of lecture. 2006-2009

Class: 50 M.D. students.

Protein phosphorylation and cell regulation (MBIO 522). Lecturer. Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine. 2005, 2007, 2009, 2011 Two hours of lecture.

Class: 6-15 senior Ph.D. students.

Signaling via Cell Adhesion (MBIO 518). Lecturer. Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine. 2006 –present. Two hours of lecture.

Class: around 10 senior Ph.D. students.

Postdoctoral Fellow Trainees:

Hui Miao, Ph.D., 1998-2002. Current Position: Assistant Professor, Department of Medicine, Case Western Reserve University School of Medicine.

Qing Li, M.D., Ph.D.-1998-2001. Current Position: Physician, Baltimore, MD.

Bih-Rong Wei, Ph.D., 2000-2004, Current Position, Senior Researcher, NCI

Eugene Myshkin, Ph.D. 2002-2005, Current Position, Senior Research Scientist at Thomson Reuters.

Emhonta Johnson, Ph.D. 2003-2005, Current position: Associate Professor, Cuyahoga Community College

Jarnail Singh, Ph.D. 2003-2006, Current position: Project Scientist, Lerner Research Institute, Cleveland Clinic Foundation

Hla Win, Ph.D. 2008-2010, Current position, Senior Research Associate, University of Southern Florida

Hong Guo, M.D. Ph.D., 2005-present

James Kaspar, Ph.D. 2012-present.

Ji Zheng, Ph.D., 2013-Present

Thesis and Preliminary Examination Committee:

Kimberly A. Krivacic, Ph.D. Candidate, Department of Pathology, 2000-2005.

Erin Millikin, Ph.D. Candidate, Department of Pharmacology, 2001-2005

Yee-Hsee Hsieh, Ph.D. Candidate, Department of Pharmacology, 2002.

Payal Gandhi, Ph.D. Candidate, Department of Pharmacology, 2003-2007.

Tara Ellison, Ph.D. Candidate, Department of Pharmacology, 2003-2007.

Hui Wang, Ph.D. Candidate, Department of Pharmacology, 2003-2008.

Feng Xue, Ph.D. Candidate, Department of Pathology, 2004-2008.

Zhenfeng Zhang, Ph.D. Candidate, Department of Pathology, 2004-2009.

Samantha Oblenader, Ph.D. Candidate, Department of Molecular Biology, 2007-2009

Reema Wahdan-Alaswad, Candidate, Department of Pharmacology, 2006-2010

Shih-Wei Chou, MS Candidate, Department of Biology, 2007-2009

Eric M. Lam, Ph.D. Candidate, Department of Pharmacology, 2007-present

Lu Yu, Ph.D. Candidate, Department of Biochemistry, 2010-Present

Meghana B. Gupta, Department of Pharmacology, 2010-present

Ashley Rettew, Department of Pathology, 2010-present

Tyler Gray, Department of Molecular Medicine, Case Western Reserve University
Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic Lerner
Research Institute, 2011

Molly Taylor, Ph.D. Candidate, Department of Pharmacology, 2012.

Invited Oversea Thesis Committee:

Helen Hauge, Ph.D. Candidate, University of Oslo, Oslo, Norway, April 2008. (Chairman of the committee)

Halvor Lauvstad Holen, Ph.D. Candidate, University of Oslo, Oslo, Norway, December 2010. (Chairman of the committee)

Chester Scholars Research Training Program:

Erin L. Simon*, 1998, Baldwin Wallace College, Current Position: Emergency Medicine, Akron General Hospital.

Terry Alexandrou*: 1999, Indiana University, Current Position: LASIK Specialist at Koch Eye Laser vision Centers in Rhode Island

Eileen Russel: 2011, Hiram College, Current Position: Senior Premed Student

*These Students are co-authors on our publications.

American Cancer Society Research Fellow:

Erin L. Simon, 1998, Baldwin Wallace College, Current Position: Physician, Akron, Ohio

Terry Alexandrou: 1999, 2000, Indiana University, Current Position: Ophthalmologist, Warwick, Rhode Island.

Kelly Pollak, 2004, Washington University, Current Position, Anesthesiologist, Salt Lake City, Utah.

INVITED SPEAKER

- 1989 The 91st AACR Meeting, Washington, D.C., Overcoming the Tumor Suppressor Gene Activity by the *Ras* and *Neu* Oncogenes in Copenhagen Rats.
- 1990 Sixth Oncogene Meeting, Hood College, Maryland. Rapid Induction of Mammary Carcinomas Following in situ *Ras* and *Neu* Oncogene Transfer.
- 1991 Department of Microbiology, Univ. of California, San Francisco. Differential mammary tumorigenicity of Neu and Ras oncogenes following in situ gene transfer.
- 1991 Bristol-Meyer Scripps Research Institute, Princeton, NJ, Interactions between Ras oncogenes and mammary carcinoma suppressor gene (MCS) in Copenhagen rats.
- 1995 La Jolla Cancer Research Foundation, La Jolla, CA. A novel matrix attachment region DNA binding motif identified using a random phage peptide library.
- 1997 Annual Meeting of America Association for Cancer Research. Eph family receptor protein tyrosine kinases in the regulation of integrin-mediated cell adhesion and migration.
- 1998 Department of Basic Medical Sciences, Purdue University, Eph kinase regulation of cell adhesion and migration: Role of focal adhesion kinase.

- 1999 Gordon Research Conference on Fibronectin, Integrins, and Related Molecules. Ventura, CA, Suppression of cell integrin-mediated cell adhesion and migration by EphB3 and EphA2 kinases.
- 1999 Department of Physiology and Biophysics, Case Western Reserve University. Eph kinase signaling in the Regulation of Integrin-Mediated Cell Adhesion, spreading and Migration.
- 2000 Department of Immunology Seminar Series, Case Western Reserve University. Negative regulation of cell adhesion, migration and proliferation: Lessons from the Eph family receptor tyrosine kinases.
- 2000 Department of Pharmacology, Case Western Reserve University. Regulation of integrin affinity and RAS/Raf/MEK/MAPK signaling cascade by Eph receptor tyrosine kinases.
- 2000 Gordon Research Conference on Signaling by Cell Adhesion Molecules, Salve Regina University, Newport, Rhode Island. Eph Kinase Regulation of Cell Adhesion, Migration and Proliferation: Role of FAK and Ras.
- 2000 36th Annual Meeting of America Society of Nephrology, Toronto, Canada. Dissecting signaling pathways initiated by Eph receptor tyrosine kinases: Catalytic activity was necessary for inhibition of cell adhesion and spreading, but dispensable for inhibition of cell migration.
- 2000 36th Annual Meeting of America Society of Nephrology, Toronto, Canada. EphA2 receptor tyrosine kinase is highly expressed in inner medullary collecting duct cells and regulates cell adhesion and morphogenesis through novel signaling pathways.
- 2001 NIH Workshop on “Genomics and Proteomics in Kidney and Urologic Diseases”, Washington D.C.. Phage display.
- 2002 Department of Cancer Research and Genomics and Gene Therapy, Berlex Biosciences, San Francisco. Eph kinase in prostate cancer growth and metastasis.
- 2002 Department of Anatomy and Massey Cancer Center, Virginia Commonwealth University. Eph kinase signaling in development and disease.
- 2002 Department of Biomedical Genetics, University of Rochester. Eph Kinase Signaling in Epithelial Cell Adhesion, Migration, and Morphogenesis: Role of Ras and FAK.
- 2002 38th Annual Meeting of America Society of Nephrology, Philadelphia, PA. EphA2 Receptor Tyrosine Kinase Regulates Renal Epithelial Cell-Cell Adhesion through Rho GTPases.
- 2003 Winship Cancer Institute Cancer Biology Seminar Series, Emory University, Atlanta, GA. Negative Regulation of tumor cell chemotaxis and proliferation: Role of FAK, Ras and Rho.
- 2003 Cleveland State University, Cleveland, OH. Receptor tyrosine kinase signaling and tumor metastasis.
- 2003 National Health Research Institute Conference on Signal Transduction. Taoyuan, Taiwan. Eph/ephrin Bidirectional Signaling in Epithelial Branching Morphogenesis.

- 2003 National Taiwan University School of Medicine, Taipei, Taiwan. Eph kinase signaling in cell adhesion, migration and tumor progression.
- 2003 Ireland Cancer Center, Case Western Reserve University. FAK and MAPK as downstream effectors of Eph kinases: Implications in prostate cancer therapy.
- 2004 10th SCBA International Symposium, Beijing, China. Eph kinase signaling and tumor progression.
- 2004 University of Michigan Comprehensive Cancer Center. Eph/ephrin bidirectional signaling in epithelial morphogenesis and tumor progression: New targets for drug discovery?
- 2004 Rutgers University, Laboratory of Cancer Research, New Jersey. Novel Signaling Pathways Initiated by Eph Kinases: Role in Cell proliferation and Migration.
- 2005 Van Aiken Institute. EphA2 Kinase Signaling Pathways Initiated by Epithelial Branching Morphogenesis and Malignant Progression.
- 2005 1st Signaling in Cancer Conference. Case Western Reserve University, Case Comprehensive Cancer Center. Rac'n Rho: Dissecting Eph Receptor Tyrosine Kinase Signaling in Cell Motility Regulation.
- 2005 Cleveland Clinic Foundation, Urology Research Conference Series, Breaking the stereotype: Eph receptor tyrosine kinases as novel tumor suppressors.
- 2006 97th American Association for Cancer Research, Washington D.C. EphA2 receptor tyrosine kinase is a tumor suppressor gene in mammalian skin.
- 2006 Nephrology and Hypertension Research Conference, University Hospital, Cleveland, Ohio. EphA/ephrin-A Bidirectional Signaling in Renal Epithelial Branching Morphogenesis.
- 2006 H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. EphA2 as a novel target for cancer therapy.
- 2007 West Virginia University, Department of Biochemistry, Morgantown, West Virginia. EphA2 Kinases: Oncogenes or Tumor Suppressor Genes?
- 2007 Pulmonary Research Conference Series, University Hospital, Cleveland, Ohio. EphA2 is a novel lung tumor suppressor gene.
- 2008 Northwestern University,. Eph kinases in epidermal cell adhesion, migration and tumorigenesis.
- 2008 Karolinska Institute, Stockholm, Sweden. Regulation of Renal Development by Eph/ephrin Bidirectional Signaling.
- 2008 University of Oslo, Oslo, Norway. Bidirectional signaling by Ephs and ephrins in development and diseases.
- 2008 South-Central University, Changsha, China. Dysregulation of Eph kinases in human cancer.

- 2008 Wake Forest University Cancer Center. The First NIH-Sponsored Conference on “Eph and Ephrin in Cancer”. Reciprocal regulation between EphA2/ephrin-A and oncogenic signaling networks.
- 2008 Regeneron Pharmaceuticals, Inc. New York. Ephrin Receptors: Oncogene or Tumor Suppressor Genes?
- 2008 Cleveland Clinic Foundation. Dual functions of EphA2 in tumor progression.
- 2009 Rheumatology Research Conference Series. MetroHealth Campus, Case Western Reserve University. Novel Role of Eph Kinases in Tumor Progression.
- 2009 West Virginia University, Cancer Center, Morgantown, West Virginia. To go or not to go: An Akt-EphA2 reciprocal regulatory loop controls tumor cell migration and invasion
- 2009 Case Comprehensive Cancer, Case Western Reserve University School of Medicine. Ligand-Dependent and -Independent Functions of EphA2 receptor tyrosine kinase in development and diseases.
- 2010 Department of Pharmacology, Case Western Reserve University School of Medicine. “Eph”ective Regulation of Tumor Invasion by a Reciprocal Regulatory Loop between EphA2 and Akt.
- 2010 Cardiovascular Research Institute, Case Western Reserve University School of Medicine. To go or not to go: An Akt-EphA2 reciprocal regulatory loop controls tumor cell migration and invasion.
- 2010 EMBO Workshop, Cell Guidance Signals in Cancer. Camogli-Portofino Vetta, Italy. Akt-EphA2 crosstalk in invasive tumor progression.
- 2010 Department of Cell Biology, Oklahoma health Science Center, University of Oklahoma. Signaling by Eph kinases.
- 2010 The Second NCI-Sponsored Conference on “Eph and Ephrin in Cancer”. Wake 2010 The Second NCI-Sponsored Conference on “Eph and Ephrin in Cancer”. Wake Forest University Cancer Center, North Carolina. MAP-ping EphA2 signaling network in cancer.
- 2010 University of Wisconsin-Madison, McArdle Laboratory for Cancer Research. Eph/ephrin bidirectional signaling in cancer initiation and progression. September 28, 2010.
- 2010 Cleveland Clinic Foundation, Department of Translational Hematology & Oncology Research (THOR). Turning Sword into Plowshare: Targeting EphA2 to Halt malignant Progression. October 5, 2010.
- 2010 University of Oslo, Institute of Molecular Biology, Targeting EphA2 for Malignant Diseases. December 15, 2010.
- 2011 University of Hawaii, Cancer Research Center of Hawaii, January 20, 2011.
- 2011 Department of Pathology, Case Western Reserve University School of Medicine. Dual roles of EphA2 kinase in malignant tumor progression. February 21, 2011.

- 2011 Lerner Research Institute, Cleveland Clinic Foundation, Department of Cancer Biology, Targeting Eph/ephrin systems in malignant disease. April 26, 2011.
- 2012 The Tisch Cancer Institute ,Mount Sinai School of Medicine. AKT-ive role of EphA2 in tumor cell dissemination. April 20, 2012.
- 2012 Institut Cochin, Université Paris Descartes, Centre National de la Recherche Scientifique, Paris, France. Eph-ephrin bidirectional signaling in epithelial homeostasis and disease. June 27, 2012.
- 2012 Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine. Mechanism-driven and structure-based development of small molecules targeting EphA2 receptor in cancer. September 21, 2012
- 2012 2nd annual Dialogue on Discovery, Case Western Reserve University School of Medicine, “Eph”ective targeting of tumor metastasis September, 2012.
- 2012 University of Kansas Cancer Center, Dual roles of EphA2 receptor in tumor progression. November 13, 2012
- 2012 University of Alabama at Birmingham, Department of Genetics. “Eph”ective targeting of tumor metastasis. November 30, 2012.
- 2013 Pennsylvania State University, College of Medicine, Biomedical Sciences Seminar Series. EphA2 paradox: Oncogene or tumor suppressor gene? Feb. 27, 2013.
- 2013 University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center. EphA2 in castration resistant prostate cancer. April, 2013.

REVIEWER FOR PROFESSIONAL JOURNALS:

- | | |
|---|--------------------------------------|
| New England of Medicine | Cancer Cell |
| Nature Genetics | Journal of Cell Biology |
| Nature Cell Biology | Oncogene |
| Nature Review Mol. Cell Biology | Cancer Research |
| Nature Review Cancer | PNAS |
| EMBO Journal | Neoplasia |
| Journal of Cell Sciences | Blood |
| Journal of Biological Chemistry | Journal of Leukocyte Biology |
| Molecular Cancer Research | British Journal of Cancer |
| International Journal of Cancer | FEBS Letter |
| Trend in Neurosciences | Cancer Chemotherapy and Pharmacology |
| BioMed Central-Immunology | Physiological Genomics |
| Biochemistry | PLoS One |
| Molecular and Cellular Biology | American Journal of Physiology |
| Nature Biotechnology | FEBS Letter |
| Nature Structural and Molecular Biology | |

GRANT REVIEWER

NATIONAL

- 1) NIH-NHLBI Special Emphasis Panel, 2002
- 2) US Department of Army, Congressionally Directed Medical Research Programs, Prostate Cancer Research Program, Pathobiology-2 Review Panel, 2003-*present*.
- 3) Veteran Administration, 2001 *ad hoc*.
- 5) American Cancer Society, Cell Structure and Metastasis Peer Review Committee, 2006-2007.
- 6) NIH-NCI: Drug Discovery and Molecular Pharmacology (DMP) study section *ad hoc*: 2006-present
- 7) NIH-NICDH: Member of Review Panel, P01 Project application, 2008
- 8) NIH-NCI: Discovery and Development P01 SEP Review, June 2009
- 9) NIH-NHLBI: P01 Program Project Review Panel 12, October 2009
- 10) NIH: NIH Director's Opportunity for Research in Five Thematic Areas (RC4), June 2010
- 11) NIH-NCI: Tumor Progression and Metastasis (TPM) study section *ad hoc*: 2009-present
- 12) NIH-NCI: Cancer Molecular Pathobiology [CAMP] study section *ad hoc*: 2011-present
- 13) NIH-NCI: Cancer Molecular Pathobiology [CAMP] *Chartered Member*: 2013 to 2019
- 14)

REGIONAL

- 1) America Heart Association, Ohio Valley, Research Review Committee 5B, 2003-2006
- 2) America Heart Association, Ohio Valley, 2000 *ad hoc*.

COMMITTEE AND PROGRAM APPOINTMENT

- 1) Member, Library Committee, MetroHealth Campus, Case Western Reserve University School of Medicine, 1997-present.
- 2) Member, Equipment Committee, MetroHealth Campus, Case Western Reserve University School of Medicine: 2001-2003.
- 3) Member, Cell Biology Program: Case Western Reserve University School of Medicine, 2002-present.
- 4) Founder and Director, Cleveland State University and MetroHealth Medical Center Joint Graduate Training Program in Biomedical Research. 2002-present.
- 5) Member, Steering committee of the Athymic Mice Facility at Case Western Reserve University School of Medicine. 2003-present
- 6) Member: Committee of Appointment, Promotion and Tenure (CAPT), MetroHealth Medical Center, Case Western Reserve University School of Medicine. 2004-2007
- 7) Member: Steering Committee of Research Oncology Training Grant (NIH-NCI T32 CA59366), 2004-2009
- 8) Member: Committee on Appointment, Promotion and Tenure (CAPT), Department of Pharmacology, Case Western Reserve University School of Medicine, 2009-present
- 9) Member: Search Committee, Associated Director of Basic Research, the Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2009-2010.
- 10) Member: Search Committee, Chief of Endocrinology Division, MetroHealth Medical Center, Case Western Reserve University School of Medicine, 2010-2011.

- 11) Member: Search Committee, Faculties in Cancer Biology and Genetics, the Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2011.
- 12) Member: Steering Committee of Cancer Biology Training Grant (NIH-NCI T32 CA59366), 20010-Present
- 13) Member: Search Committee, Endowed Chair in Prostate Cancer Research, Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine. 2012
- 14) Member: Physician Scientist Program, MetroHealth Medical Center, Case Western Reserve University School of Medicine.

MEETING ORGANIZER AND MODERATORS:

- 1) Moderator, Pathways/Drug Targets, Application Breakout Session, NIH Workshop on “Genomics and Proteomics in Kidney and Urologic Diseases”, July 2001.
- 2) Co-Chair, Organizing Committee, Fourth Annual Research Conference, MetroHealth Medical Center, Case Western Reserve University. Aug. 2001.
- 3) Chair, Organizing Committee, Fourth Annual Research Conference, MetroHealth Medical Center, Case Western Reserve University. Aug. 2002-2006.
- 4) Chair, Tumor Biology Session, First NCI Meeting on Eph-Ephrin in Cancer, Wake Forest University Cancer Center, July 2008
- 5) Chair, Structure and Signaling Session, Second NCI Meeting on Eph-Ephrin in Cancer, Wake Forest University Cancer Center, June 2010

PROFESSIONAL SOCIETIES:

American Association for Cancer Research, 2001-present.
American Association for Advancement of Science, 1991-present.
Society of Chinese Bioscientists in America, 2004 to present
International Chemical Biology Society 2012-present

SELECTED PUBLICATIONS:

- Wang, B., Kennan, W.S., Yasukawa-Barnes, J., Lindstrom, M.J., and Gould, M.N. (1991). Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. **Cancer Research** 51, 5649-5654.
- Wang, B. C., W. S. Kennan, J. Yasukawa-Barnes, M. J. Lindstrom, and M. N. Gould. 1991. Carcinoma induction following direct in situ transfer of v-Ha-ras into rat mammary epithelial cells using replication-defective retrovirus vectors. **Cancer Res.** 51:2642-2648.
- Wang, B., Kennan, W.S., Yasukawa-Barnes, J., Lindstrom, M.J., and Gould, M.N. (1991). Overcoming the activity of mammary carcinoma suppressor gene in Copenhagen rats by v-H-ras oncogene transfer into mammary epithelial cells in situ. **Cancer Research** 51, 5298-5303.
- Gould, M.N., Clifton, K.H., Kamiya, K., Wang, B., and Zhang, R. (1991). Quantitative and molecular comparison of initiation frequency of mammary carcinogenesis by

- radiation and chemical carcinogens. **Radiation & Environmental Biophysics** 30, 221-223.
- Wang, B., Kennan, W.S., Yasukawa-Barnes, J., Lindstrom, M.J., and Gould, M.N. (1992). Difference in the response of neu and ras oncogene-induced rat mammary carcinomas to early and late ovariectomy. **Cancer Research** 52, 4102-4105.
- Zhai, Y.F., Beittenmiller, H., Wang, B., Gould, M.N., Oakley, C., Esselman, W.J., and Welsch, C.W. (1993). Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. **Cancer Research** 53, 2272-2278.
- Koivunen, E., Wang, B., Dickinson, C.D., and Ruoslahti, E. (1994). Peptides in cell adhesion research. **Methods in Enzymology** 245, 346-369.
- Gould, M.N., Moore, C.J., Zhang, R., Wang, B., Kennan, W.S., and Haag, J.D. (1994). Limonene chemoprevention of mammary carcinoma induction following direct in situ transfer of v-Ha-ras. **Cancer Research** 54, 3540-3543.
- Koivunen, E., Wang, B., and Ruoslahti, E. (1994). Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. **Journal of Cell Biology** 124, 373-380.
- Thompson, K.A., Wang, B., Argraves, W.S., Giancotti, F.G., Schranck, D.P., and Ruoslahti, E. (1994). BR140, a novel zinc-finger protein with homology to the TAF250 subunit of TFIID. **Biochemical & Biophysical Research Communications** 198, 1143-1152.
- Koivunen, E., Wang, B., and Ruoslahti, E. (1995). Phage libraries displaying cyclic peptides with different ring sizes: Ligand specificities of the RGD-directed integrins. **Nature Biotechnology** 13, 265-268.
- Wang, B., Dickinson, L.A., Koivunen, E., Ruoslahti, E., and Kohwi-Shigematsu, T. (1995). A novel matrix attachment region DNA binding motif identified using a random phage peptide library. **Journal of Biological Chemistry** 270, 23239-23242.
- Petosa, C., Masters, S.C., Bankston, L.A., Pohl, J., Wang, B., Fu, H., and Liddington, R.C. (1998). 14-3-3zeta binds a serine-phosphorylated Raf peptide and an unphosphorylated peptide via its conserved amphipathic groove. **Journal of Biological Chemistry** 273, 16305-16310.
- Singh, R., Wang, B., Shirvaikar, A., Khan, S., Kamat, S., Schelling, J. R., Konieczkowski, M., and Sedor, J. (1999). Rho family GTPases physically associate with interleukin-1 receptor cytosolic domain. Coordinate organization of actin cytoskeleton and kinase pathways drive mesenchymal cell activation. **Journal of Clinical Investigation** 103:1561-1570.
- Zou, J.X., Wang, B., Andreas H. Zisch, Elena B. Pasquale and Erkki Ruoslahti. (1999). An Eph receptor regulates integrin activity through R-Ras. **Proceedings of National Academy of Science** 96:13813-13818.

- Wang, B., Zhang, L., Liu, Y.-C., Jelinek, T., Ruoslahti, E., and Fu, H. (1999). Isolation of high affinity antagonists of 14-3-3 proteins by phage display. **Biochemistry** 38:12499-12504.
- Zhang, L. Wang, H., Masters, S.C., Wang, B., Barbieri, J. T., and Fu, H. (1999). Residues of 14-3-3 ζ required for activation of exoenzyme S of *Pseudomonas aeruginosa*. **Biochemistry** 37:12159-12164.
- Zantek, N.D., Azimi, M., Fedor-Chaiken, M., Wang, B., Brackenbury, R., and Kinch, M.S. (1999). E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. **Cell Growth and Differentiation**. 10:629-638.
- Wang, B., Zou, J. X., Bek-Rylander, B., and Ruoslahti, E. (2000). R-Ras contains a proline-rich site that binds to Nck and is required for integrin activation by R-Ras. **Journal of Biological Chemistry** 275:5222-5228.
- Miao, H., Burnett, E., Kinch, M. S., Simon, E., and Wang, B. (2000). EphA2 kinase activation suppresses integrin function and causes focal adhesion kinase dephosphorylation. **Nature Cell Biology** 2:62-69.
- Khan, S., Koepke, A., Jarad, G., Schlessman, K., Cleveland, R. P., Wang, B., Konieczkowski, M., and Schelling, J. R. (2001). Apoptosis and JNK activation are differentially regulated by Fas expression level in renal tubular epithelial cells. **Kidney International** 60:65-76.
- Miao, H., Wei, B.-R., Peehl, D. M., Li, Q., Burnett, E., Alexandrou, T., Sedor, J. R., Schelling, J. R., and Wang, B. (2001). EphA kinase activation inhibits Ras/MAPK pathway. **Nature Cell Biology** 3:527-530.
- Zantek, N. D., Walker-Daniels, J., Stewart, J., Hansen R. K., Robinson D., Miao, H., Wang, B., Kung, H.J., Bissell, M. J., Kinch, M. S. (2001). MCF-10A-NeoST: A New Cell System for Studying Cell-ECM and Cell-Cell Interactions in Breast Cancer. **Clinical Cancer Research** 7:3640-3648.
- Jarad G, Wang B. Khan S, DeVore J, Miao H, Wu K, Nishimura SL, Wible BA, Konieczkowski M, Sedor JR, Schelling JR (2002). Fas activation induces renal tubular epithelial cell α 8 integrin expression and function in the absence of apoptosis. **Journal of Biological Chemistry** 277:47826-47833.
- Han, D. C., Shen, T. L., Miao, H., and Wang, B. Guan, J.-L. (2002). EphB1 associate with Grb7 and regulate cell migration. **Journal of Biological Chemistry** 277:45655-45661.
- Myshkin, E. and Wang, B. (2003). Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach. **Journal of Chemical Information and Computer Sciences** 43:1004-1010.
- Deroanne, C., Valérie Vouret-Craviari, V., Wang, B. and Pouysségur J. (2003). EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway. **Journal of Cell Sciences** 116:1367-1376.

- Miao, H., Nickel, C., Cantley, L. G., Leslie A. Bruggman, ¹Laura N. Bennardo and Wang, B. (2003). EphA Kinase Activation Regulates HGF-Induced Epithelial Branching Morphogenesis. **Journal of Cell Biology** 162:1681-1692.
- Miao, H., Guan, J.-L., Shen, T. L., Strebhardt, K., Paquale, E. B., and Wang, B. Inhibition of integrin-mediated cell adhesion and spreading, but not migration requires the catalytic activity of EphB3 kinase. (Published online Nov. 2004). **Journal of Biological Chemistry**. 280:923-932.
- Iida, H., Honda, M., Kawai, H. F., Yamashita, T., Shiota, Y., Miao, H., Wang, B., Wang, B. and Kaneko, H. (2005). Ephrin-A1 Expression Contributes to the Malignant Characteristics of α -Fetoprotein-Producing Hepatocellular Carcinoma. **Gut** 54:843-851.
- Lakhe-Reddy, S., Khan, S., Konieczkowski, M., Jarad, G., Wu, K.L., Reichardt, L.F., Takai, Y., Bruggeman, L.A., Wang, B., Sedor, J.R. et al. (2006). β 8 integrin binds Rho GDP dissociation inhibitor-1 and activates Rac1 to inhibit mesangial cell myofibroblast differentiation. **Journal of Biological Chemistry** 281(28):19688-99.
- Guo, H., Miao, H., Gerber, L., Singh, J., Denning, M. F., Gilliam, A. C., and Wang, B. (2006) Disruption of EphA2 kinase led to increased susceptibility to skin carcinogenesis. **Cancer Research** 66:7050-7058.
- Tandon R, Levental I, Huang C, Byfield FJ, Ziembicki J, Wang, B., Schelling JR, Bruggeman LA, Sedor JR, Janmey PA, Miller RT. (2007) HIV infection changes glomerular podocyte cytoskeletal composition and results in distinct cellular mechanical properties. **American Journal Physiology Renal Physiology** 2007 292:F701-10.
- Wang B. (2008). PTPases: “Eph”ective arbitrators of attraction. **Blood** (Invited Expert Commentary for *Inside Blood*) 112:455-456. PMID: 18650455
- Fu W., McCormick, t., Qi, X., Luo, L., Zhou, L., Li, X., Wang, B. Gibbons, G.E., Fadi W. Abdul-Karim, F. W., Gorodeski, G. I. (2009). Activation of P2X₇-Mediated Apoptosis Inhibits DMBA/TPA-induced Formation of Skin Papillomas and Cancer in Mice. **BioMed Central-Cancer** 9:114. PMID: 19379509
- Himanen J, Goldgur Y, Myshkin E, Miao H, Nguyen M, Rajashankar KR, Wang, B.*, and Nikolov, D.* (2009). Ligand Recognition by A-Class Eph Receptors: Crystal Structures of the EphA2 Ligand-Binding Domain and the EphA2/ephrin-A1 Complex. **EMBO Report** 10:722-728, PMID: 19525919
- *Co-corresponding authors.
- Jun G., Guo, G., Klein, E.E.K., Klein, R., Wang, J.J., Mitchell, P., Miao, H., Lee, K., Joshi, T., Buck, M., Chugha, P., Bardenstein, D., Klein, A., Bailey-Wilson, J.E., Gong, X., Spector, T.D., Andrew, T., Hammond, C.H., Iyengar, S.K., and Wang, B. (2009). Converging evidence from mice and humans show that EphA2 is associated with age-related cataract. **PLoS Genetics**. (Published online on July 31, 2009).
- Miao H., Li D.-Q., Mukherjee A, Guo, H., Petty, A. Cutter J, Basilion J, Sedor J, Wu, J., Danielpour, D., Sloan, A. E., Cohen, M., and Wang, B. (2009). EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt, **Cancer Cell**, 16:9-20, PMID: 19573808.
- *This article was featured in **Nature** (461:149, 2009) under Research Highlights.

- Song K, Wang H, Krebs TL, Wang B, Kelley TJ, and Danielpour D. (2010). Dihydrotestosterone Selectively Reverses Smad3-mediated/TGF- β -induced Responses through Transcriptional Downregulation of Smad3 in Prostate Epithelial Cells. **Molecular Endocrinology**, 24:2019-29. PubMed PMID:20739403; PubMed Central PMCID: PMC2954637.
- Khan, S., Lakhe-Reddy, S., McCarty, J. H., Sorenson, C. M., Sheibani, A., Reichardt L. F., Kim, J., Wang, B., Sedor, J. R., and Schelling, J. R. (2010). Mesangial Cell Integrin $\alpha\beta 8$ Provides Glomerular Endothelial Cell Cytoprotection by Sequestering TGF- β and Regulating PECAM-1. **American Journal of Pathology** 178 :609-20. PubMed PMID:21281793.
- Lu X, Guo H, Molter J, Miao H, Gerber L, Hu Y, Barnes EL, Vogel H, Lee Z, Luo G, Wang B. (2011) Alpha-fetoprotein-thymidine kinase-luciferase knockin mice: A novel model for dual modality longitudinal imaging of tumorigenesis in liver. **Journal of Hepatology** [Epub ahead of print 2010 Dec 7] PubMed PMID: 21354236.
- Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. (2011). A Novel Extracellular Hsp90 Mediated Co-Receptor Function for LRP1 Regulates EphA2 Dependent Glioblastoma Cell Invasion. **PLoS One** 6:e1764 PMID:21408136
- Wang, B. (2011). Cancer cells exploit Eph kinases for invasion and metastasis: Tales of unwitting partners. **Science Signaling** 4:pe28.
- Miao, H. and Wang, B. (2012). EphA receptor signaling—Complexity and emerging themes. **Seminars in Cell and Developmental Biology**. 23:16-25. Invited Review. Published online Oct. 21, 2011. PMID:22244754.
- Lin, S., Wang, B. Getsios, S. (2012). Eph/ephrin signaling in epidermal differentiation and disease. **Seminars in Cell and Developmental Biology**. 23:92-101. Invited Review. Published online Oct. 21, 2011, PMID:22040910
- Lee, H.J., Hota, P.K., Chugha, P., Guo, H., Miao, H., Zhang, L., Kim, S.J., Stetzig, L., Wang B.*, and Buck, M*. (2012). Refined NMR structure of a heterodimeric SAM:SAM complex. Characterization and manipulation of the EhpA2 interface leads to new cellular functions of SHIP2. **Structure** 11:41-55. PMID:22244754.
- *Co-corresponding authors.
- Tian H, Lu X, Guo H, Corn D, Molter J, Wang B, Luo G, Lee Z. (2012). Radio-deoxynucleoside Analogs used for Imaging tk Expression in a Transgenic Mouse Model of Induced Hepatocellular Carcinoma. **Theranostics**. 2:597-606.
- Petty, A.*, Myshkin, E.*, Qin, H.*, Guo, H., Miao H., Tochtrop, G.P., Hsieh, J.-T., Page, P., Acharya, C., MacKerell, A., Ficker, E., Song, J., and Wang, B. (2012). A Small Molecule Agonist of EphA2 Receptor Tyrosine Kinase Inhibits Tumor Cell Migration In Vitro and Prostate Cancer Metastasis In Vivo. **PLoS ONE** 7(8): e42120. doi:10.1371/journal.pone.0042120. *Equal contributors.
- Miao H., Guo, H., Petty, A. Gale, N.W., Yancopoulos, G., Lee, J. and Wang, B. (2013) Akt-EphA2 signaling axis regulates glioma stem-like cell properties and promotes diffuse intracranial invasion in vivo. **Oncogene** (in press).
- Guo, H., Petty, A., Miao, H., and Wang, B. (2013). Oncogenic and tumor suppressor roles of EphA1 and EphA2 receptors in hepatocellular carcinogenesis. **Nature Medicine** (submitted).

BOOK CHAPTER:

- Gould, M. N., Wang, B., and Moore, C. J. (1989). Modulation of mammary carcinogenesis by enhancer and suppressor genes. In: Colburn, N.H. (ed.) Genes and Signal Transduction in Multistage Carcinogenesis. MerceL Dekker, Inc., New York and Basel.
- Wang B. and Miao H. (2010). Eph/ephrin signaling in postnatal growth of epithelial tissue. In: Preedy, V.R. (ed.) The Handbook of Growth and Growth Monitoring in Health and Disease. Springer, New York / Heidelberg.

SELECTED ABSTRACTS:

- 1) Wang, B., Kennan, W.S., Yasukawa-Barnes, J., Lindstrom, M.J., and Gould, M.N. Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. *Annual Meeting of American Association for Cancer Research, 1989*
- 2) Wang, B., Kennan, W.S., Yasukawa-Barnes, J., Lindstrom, M.J., and Gould, M. N. Overcoming the activity of mammary carcinoma suppressor gene in Copenhagen rats by v-H-ras oncogene transfer into mammary epithelial cells in situ. *Annual Meeting of American Association for Cancer Research, 1990.*
- 3) Wang, B., Kennan, W.S., Yasukawa-Barnes, J., Lindstrom, M.J., and Gould, M. N. Quantitative analyses of oncogenic potency of Neu and Ras oncogene in rat mammary gland. *Sixth Annual Meeting on Oncogenes 1990.*
- 4) Wang, B., and Ruoslahti, E. $\alpha 6\beta 4$ integrin is a laminin receptor. Gordon Conference on Basement Membrane, 1994.
- 5) Wang, B., Pasquale, E. B., and H. Miao. Activation of EphB3 or EphA2 kinase inhibits cell adhesion and migration by inactivating integrins. Annual Meeting of America Society of Nephrology, 1998.
- 6) Li, Q., Miao, H., Burnett, E., Schelling, J. R., Sedor, J. R., and Wang, B. Targeting EphA2 kinase with an agonistic peptide isolated from phage display libraries. Annual Meeting of America Society of Nephrology, 1999.
- 7) Miao, H., and Wang, B. Focal adhesion kinase (FAK) associates with and is inactivated by Eph receptor tyrosine kinases in renal epithelial cells. . Annual Meeting of America Society of Nephrology, 1999.
- 8) Li, Q., Miao, H., Schelling, J., Wang, B., & Sedor, J. Affinity-selected Fc γ R-blocking peptides from phage display libraries are potential reagents for therapy of glomerulonephritis (GN). Annual Meeting of the American Society of Nephrology, November 1 - 8, 1999, Miami Beach, Florida, USA, Abstract pp. 531A
- 9) Miao, H., Pasquale, E.B. & Wang, B. Activation of EphB3 kinase inhibits cell adhesion and migration by inactivating integrins. *Keystone symposia on oncogene networks in signal transduction.* Keystone, Colorado, USA. Abstract pp. 146, 1999.
- 10) Miao, H., Peehl, D. M., and Wang, B. EphA2 kinase activation suppresses prostate epithelial cell proliferation by attenuating Ras/Raf/MEK/MAPK signaling pathway. 91st Annual Meeting of America Association for Cancer Research, 2000.

- 11) He, P., Islam, N., Wang, B., and Greenfield, E. M. (2001). Use of Phage Display peptides that inhibit differentiation. Annual Meeting of ASBMR.
- 12) Wang, B., Li, Q., Nikolov, D., and B.-R. Wei. 2001. IgG Fusion Peptide Agonists of EphA2 Receptor Tyrosine Kinase as Novel Therapeutics against Prostate Cancer Progression. Eighth Annual Meeting of CaP CURE13) Wang, B., C. Nickel, C., Cantley, L. G., and Miao, H.. (2001). EphA2 kinase activation inhibit renal epithelial branching morphogenesis. Joint Meeting of British Society of Cell Biology and Developmental Biology.
- 14) He, P., Wang, B., and Greenfield, E. M. (2002). Use of Phage Display peptides that inhibit differentiation. Annual Meeting of ASBMR.
- 15) Wei, B.-R. and Wang B. (2003). Suppression of prostate cancer cell chemotaxis by Eph kinase. 94th Annual Meeting of American Association for Cancer Research.
- 16) Singh, J. and Wang, B. Both EphA2 and EphA1 are sufficient in mediating suppression of Erk activity in MEFs. 96th Annual Meeting of America Association for Cancer Research, Anaheim, California, 2005.
- 17) Singh, J. and Wang, B. Both EphA2 and EphA1 are sufficient in mediating suppression of Erk activity in MEFs. 96th Annual Meeting of America Association for Cancer Research, Anaheim, California, 2005.
- 18) Miao, H. and Wang, B. Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. 96th Annual Meeting of America Association for Cancer Research, Anaheim, California, 2005.
- 19) J. R. Schelling, S. Lakhe-Reddy, S. Khan, M. Konieczkowski, G. Jarad, K. L. Wu, L. A. Bruggeman, B. Wang, J. R. Sedor. (2005) β 8 Integrin Binds RhoGDI α and Activates Rac1 To Inhibit Mesangial Cell Myofibroblast Differentiation. J. Am. Soc. Nephrology 16:436A.
- 20) Luo, G., Wang, B., Lu, X., Salem, N. ,Guo, H., Molter, J., Majewski. S.. Weisenberger, A., Lee, Z. (2006). Multimodal Imaging of Transgenic Mice for Induced Hepatocellular Carcinoma
- 21) RT Miller, C Huang, L Bruggeman, Y Ding, P Janmey, JR Sedor, B Wang, JR Schelling. (2007) Abnormal substrate sensing, integrin-mediated adhesion, and cell mechanics in HIVAN podocytes. J. Am. Soc. Nephrology 18: in press
- 22) Wang, B., Miao, H., Gerber, L., Li, D.-Q. and Guo, H. (2007). EphA2 Receptor Tyrosine Kinase Is a Novel Lung Tumor Suppressor Gene. Keystone Symposia, Mouse Model of Human Cancer.
- 23) Guo, H., Gerber, L., Miao, H., Chen, X., Iida, H., and Wang, B. (2008). EphA2 is a liver tumor suppressor gene in mice and humans. First Conference on Eph/ephrin in Cancer. Wake Forest University, 2008.
- 24) Petty, A and Wang, B. (2010). Dual function of EphA2 receptor in colorectal tumorigenesis. Second Conference on Eph/ephrin in Cancer. Wake Forest University.
- 25) Guo, H. and Wang, B. (2011). Discovery and characterization of a novel small molecule agonist for EphA2. Molecular Targets and Cancer Therapeutics. AACR-NCI-EORTC International Conference.
- 26) Miao H., Guo, H., Petty, A. Gale, N.W., Yancopoulos, G., Lee, J. and Wang, B. (2012) Akt-EphA2 signaling axis regulates glioma stem-like cell properties and promotes diffuse intracranial invasion in vivo. WIN Symposium, Palais des Congrès, Paris, FRANCE.

- 27) Petty, A. and Wang, B. (2012) Ligand-independent EphA2 signaling through Akt is preferentially activated in prostate cancer bone metastases and is important for tumor growth. AACR Special Conference "Advances in Prostate Cancer Research", Orlando, FL.
- 28) Miao H., Guo, H., Petty, A. Gale, N.W., Yancopoulos, G., Lee, J. and Wang, B. (2013) Akt-EphA2 signaling axis regulates glioma stem-like cell properties and promotes diffuse intracranial invasion in vivo. AACR Special Conference "Tumor Invasion and Metastasis", San Diego, CA.